Published in Radiat Oncol on March 15, 2015
Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys (1995) 15.12
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol (2009) 10.52
Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys (1999) 4.24
Complication probability as assessed from dose-volume histograms. Radiat Res Suppl (1985) 3.85
A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys (2001) 2.85
Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys (2010) 2.48
Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine. Int J Radiat Oncol Biol Phys (2006) 2.48
Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. Int J Radiat Oncol Biol Phys (2008) 2.13
Radiation-induced xerostomia in patients with head and neck cancer: a literature review. Cancer (2006) 2.12
Quantitative dose-volume response analysis of changes in parotid gland function after radiotherapy in the head-and-neck region. Int J Radiat Oncol Biol Phys (2001) 1.63
Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy. Int J Radiat Oncol Biol Phys (2004) 1.50
A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer (2010) 1.42
Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: a randomized controlled trial. Radiother Oncol (2012) 1.26
Parotid gland function after radiotherapy: the combined michigan and utrecht experience. Int J Radiat Oncol Biol Phys (2010) 1.21
Scintigraphic assessment of early and late parotid gland function after radiotherapy for head-and-neck cancer: a prospective study of dose-volume response relationships. Int J Radiat Oncol Biol Phys (2004) 1.10
Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life. Radiat Oncol (2008) 1.09
Lyman-Kutcher-Burman NTCP model parameters for radiation pneumonitis and xerostomia based on combined analysis of published clinical data. Phys Med Biol (2008) 1.06
Quality of life and salivary output in patients with head-and-neck cancer five years after radiotherapy. Radiat Oncol (2007) 1.04
Quantitative analysis of normal tissue effects in the clinic (QUANTEC) guideline validation using quality of life questionnaire datasets for parotid gland constraints to avoid causing xerostomia during head-and-neck radiotherapy. Radiother Oncol (2013) 1.03
The contribution of oral minor mucous gland secretions to the volume of whole saliva in man. Arch Oral Biol (1973) 1.03
Late term tolerance in head neck cancer patients irradiated in the IMRT era. Radiat Oncol (2013) 1.02
The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy. Radiother Oncol (2008) 0.97
Dose-response analysis of parotid gland function: what is the best measure of xerostomia? Radiother Oncol (2013) 0.93
Evidence-based review: quality of life following head and neck intensity-modulated radiotherapy. Radiother Oncol (2010) 0.93
The impact of late treatment-toxicity on generic health-related quality of life in head and neck cancer patients after radiotherapy. Oral Oncol (2011) 0.90
Scintigraphic assessment of salivary function after intensity-modulated radiotherapy for head and neck cancer: correlations with parotid dose and quality of life. Oral Oncol (2012) 0.89
Scintigraphy in prediction of the salivary gland function after gland-sparing intensity modulated radiation therapy for head and neck cancer. Radiother Oncol (2008) 0.89
Quantitative salivary gland scintigraphy. J Nucl Med Technol (1999) 0.88
Comments on the use of the Lyman-Kutcher-Burman model to describe tissue response to nonuniform irradiation. Int J Radiat Oncol Biol Phys (2000) 0.86
Impact of head and neck cancer adaptive radiotherapy to spare the parotid glands and decrease the risk of xerostomia. Radiat Oncol (2015) 0.85
Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes. Radiat Oncol (2014) 0.84
Time trial: a prospective comparative study of the time-resource burden for three-dimensional conformal radiotherapy and intensity-modulated radiotherapy in head and neck cancers. J Cancer Res Ther (2009) 0.83
Accuracy requirements for head and neck intensity-modulated radiation therapy based on observed dose response of the major salivary glands. Radiother Oncol (2009) 0.80
Normal tissue complication probability model parameter estimation for xerostomia in head and neck cancer patients based on scintigraphy and quality of life assessments. BMC Cancer (2012) 0.78